title: Cancer risks among the users of ergot-derived dopamine agonists for Parkinson's disease, a nationwide population-based survey.
abstract: BACKGROUND
  Factors of cancer occurrence among Parkinson disease patients are still not well known, although genetic predilection has been investigated. The aim of this study is to evaluate the medication effect of dopamine agonists of Parkinson disease on incidence of cancers from the Taiwan National Health Insurance Research Database.
  
  
  METHODS
  We conducted a population-based nested case-control study by using the resources of the Taiwanese National Health Insurance from 1996 to 2000 and analyzed the prevalence of cancer among patients with Parkinson disease. A nested analysis was then implemented among those patients with both Parkinson disease and cancer, focusing separately on the use of ergot- and nonergot-derived-dopamine agonists.
  
  
  RESULTS
  We reviewed 6211 patients with Parkinson's disease and found 329 patients with cancer. The ergot-derived dopamine agonists users were associated with an increased odds ratio for cancer, compared with nonergot-derived dopamine agonist users, with an adjusted odds ratio of 2.16 (95% confidence interval, 1.55-2.99). Among all the cancer types, we observed the higher occurrence of liver cancer among the ergot-derived dopamine agonist users.
  
  
  CONCLUSIONS
  The association of ergot-derived-dopamine agonist use and cancers, especially the liver cancers, has provided us the information to further understand the drug-cancer interaction. We hope this result would prompt further investigations on the risk and benefit of the dopamine agonists use among the Parkinson's disease patients.
authors.affiliation: Department of Neurology, Cardinal Tien Hospital, New Taipei City, Taiwan; School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.
authors.forename: Vinchi
authors.initials: V
authors.lastname: Wang
authors.affiliation: Department of Neurology, Cardinal Tien Hospital, New Taipei City, Taiwan; School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.
authors.forename: Tzu-Hao
authors.initials: TH
authors.lastname: Chao
authors.affiliation: Section of Radiation Oncology, Cardinal Tien Hospital, Taiwan.
authors.forename: Chung-Chih
authors.initials: CC
authors.lastname: Hsieh
authors.affiliation: Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan.
authors.forename: Che-Chen
authors.initials: CC
authors.lastname: Lin
authors.affiliation: Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan. Electronic address: d10040@mail.cmuh.org.tw.
authors.forename: Chia-Hung
authors.initials: CH
authors.lastname: Kao
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D018672:Community Health Planning; D018491:Dopamine Agonists / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009313:National Health Programs / Q000706:statistics & numerical data; D009369:Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D016017:Odds Ratio; D010300:Parkinson Disease / Q000188:drug therapy*; D012307:Risk Factors; D013624:Taiwan / Q000453:epidemiology
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists
keywords: Cancer risks; Dopamine agonists; Parkinson's disease